Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bevacizumab with Docetaxel-Based Regimens in Adjuvant Breast Cancer
NCT00365365Phase 2Completed
- Sponsor
- Sanofi
- Start
- Aug 2006
- Primary completion
- Oct 2011
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of bevacizumab in breast cancer (3 arms), sponsored by Sanofi. Primary endpoint: Number of Participants With Grade 3-4 Clinical Congestive Heart Failure (CHF) up to 3 years. Started Aug 2006; status: completed.
02
Drugs
bevacizumab
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT00365365.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00365365.